cycE/CCNE Cancer Research Results

cycE/CCNE, Cyclin E: Click to Expand ⟱
Source:
Type:
Cyclin E regulates multiple downstream molecules, such as the retinoblastoma susceptibility gene (RB1) and the transcription factor E2F.
Cyclin E (Cyclin E1 and Cyclin E2) is the key regulator of the late G1 → S-phase transition.
Cyclin E is a prognostic marker in breast cancer, its altered expression increased with the increasing stage and grade of the tumor.
Cyclin E is a regulatory protein that plays a critical role in the cell cycle, particularly in the transition from the G1 phase to the S phase. Its expression levels can significantly influence cancer progression and patient prognosis.

Cyclin E expression is frequently elevated in various cancers and is generally associated with poor prognosis. Its role in promoting cell cycle progression makes it a potential biomarker for tumor aggressiveness and patient outcomes.


Lung, Lung Cancer: Click to Expand ⟱
Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4)
Scientific Papers found: Click to Expand⟱
6858- FBZ,    Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells
- in-vitro, Lung, A549
eff↑, mt-ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, PARP↑, TumCCA↑, cycA1/CCNA1↓, cycE/CCNE↓,
8233- LCA,    Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer
- in-vitro, Lung, NA
TumCP↓, selectivity↑, TumCCA↑, Apoptosis↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, BAX↑, PARP1↑, Casp3↑, Bcl-2↓, MAPK↓, FBXO5/EMI1↓, TumVol↓, TumW↓, toxicity↓,
3044- SK,    Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1/CCND1↓, cycE/CCNE↓,
3415- TQ,    The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations
- in-vitro, Lung, H446
tumCV↓, TumCCA↑, ROS↓, CycB/CCNB1↑, CycD3↑, cycA1/CCNA1↓, cycE/CCNE↓, cDC2↓, antiOx↑, PARP↓, NRF2↓, ARE/EpRE↑, eff↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

FBXO5/EMI1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ARE/EpRE↑, 1,   NRF2↓, 1,   ROS↓, 1,   mt-ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 2,   Casp3↑, 3,   Casp7↑, 1,   Casp9↑, 1,   MAPK↓, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↓, 1,   PARP↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 2,   CycD3↑, 1,   cycE/CCNE↓, 4,   TumCCA↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cDC2↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 2,   selectivity↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 35

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycE/CCNE, Cyclin E
1 Fenbendazole
1 Licochalcone A
1 Shikonin
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:15  Cells:%  prod#:%  Target#:378  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page